medigraphic.com

2012, Number 1

Next >>

Rev Esp Cienc Salud 2012; 15 (1)

The viral vectors and the transgenesis

Legorreta-Herrera M, Martínez-Flores F, Hernández SF, Zentella-Dehesa A

Language: Spanish
References: 49
Page: 5-14
PDF size: 362.25 Kb.


ABSTRACT

Viral vectors constitute the most efficient vehicles to transfer genes, they make possible to specifically modify cells or tissues to induce the expression of therapeutic genes. Actually, different virus to transduce permanent or temporally transgenes are studied. Those virus include recombinant, adenoviruses, adeno associated virus, retrovirus, lentivirus and herpes virus. The vector selection depends on the efficiency and use of the transgen. It is also important to consider its easy, safe and stable production.
In this work, we present the biology of virus, the basis for its genetic manipulation and the potential application in transgenesis models. Some of these factors could be critical elements to take decisions on transgenesis procedures.


REFERENCES

  1. Mulligan, RC. The basic science of gene therapy. Science 1993;260:926-32.

  2. Jolly, D. Viral vector systems for gene therapy. Cancer Gene Ther 1994;1:51-64.

  3. Gao, X and Huang, L. Cationic liposome-mediated gene transfer. Gene Ther 1995;2:710-22.

  4. Warnock, JN, Daigre, C and Al-Rubeai, M. Introduction to viral vectors. Methods Mol Biol 2011;737:1-25.

  5. Navarro, J, Oudrhiri, N, Fabrega, S and Lehn, P. Gene delivery systems: Bridging the gap between recombinant viruses and artificial vectors. Adv Drug Deliv Rev 1998;30:5-11.

  6. Rowe, WP, Huebner, RJ, Gilmore, LK, Parrott, RH and Ward, TG. Isolation of a cytopathogenic agent from human adenoids undergoing spontaneous degeneration in tissue culture. Proc Soc Exp Biol Med 1953;84:570-3.

  7. Young, LS, Searle, PF, Onion, D and Mautner, V. Viral gene therapy strategies: from basic science to clinical application. J Pathol 2006;208:299-318.

  8. Lundstrom, K. Latest development in viral vectors for gene therapy. Trends Biotechnol 2003;21:117-22.

  9. Schiedner, G, Morral, N, Parks, RJ, et al. Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity. Nat Genet 1998;18:180-3.

  10. Stecher, H, Shayakhmetov, DM, Stamatoyannopoulos, G and Lieber, A. A capsid-modified adenovirus vector devoid of all viral genes: assessment of transduction and toxicity in human hematopoietic cells. Mol Ther 2001;4:36-44.

  11. Bergelson, JM, Cunningham, JA, Droguett, G, et al. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 1997;275:1320-3.

  12. Tomko, RP, Xu, R and Philipson, L. HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. Proc Natl Acad Sci U S A 1997;94:3352-6.

  13. Wickham, TJ, Mathias, P, Cheresh, DA and Nemerow, GR. Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell 1993;73:309-19.

  14. Hutchins, B, Sajjadi, N, Seaver, S, Shepherd, A, Bauer, SR, Simek, S, Carson, K and Aguilar-Cordova, E. Working toward an adenoviral vector testing standard. Mol Ther 2000;2:532-4.

  15. Bett, AJ, Haddara, W, Prevec, L and Graham, FL. An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3. Proc Natl Acad Sci U S A 1994;91:8802-6.

  16. Graham, FL, Smiley, J, Russell, WC and Nairn, R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 1977;36:59-74.

  17. Lusky, M, Christ, M, Rittner, K, et al. In vitro and in vivo biology of recombinant adenovirus vectors with E1, E1/E2A, or E1/E4 deleted. J Virol 1998;72:2022-32.

  18. O’Neal, WK, Zhou, H, Morral, N, et al. Toxicological comparison of E2a-deleted and first-generation adenoviral vectors expressing alpha1-antitrypsin after systemic delivery. Hum Gene Ther 1998;9:1587-98.

  19. Andrews, JL, Kadan, MJ, Gorziglia, MI, Kaleko, M and Connelly, S. Generation and characterization of E1/E2a/E3/E4-deficient adenoviral vectors encoding human factor VIII. Mol Ther 2001;3:329-36.

  20. Morsy, MA and Caskey, CT. Expanded-capacity adenoviral vectors—the helper-dependent vectors. Mol Med Today 1999;5:18- 24.

  21. Kotin, RM, Menninger, JC, Ward, DC and Berns, KI. Mapping and direct visualization of a region-specific viral DNA integration site on chromosome 19q13-qter. Genomics 1991;10:831-4.

  22. Samulski, RJ, Chang, LS and Shenk, T. Helper-free stocks of recombinant adeno-associated viruses: normal integration does not require viral gene expression. J Virol 1989;63:3822-8.

  23. Rabinowitz, JE and Samulski, J. Adeno-associated virus expression systems for gene transfer. Curr Opin Biotechnol 1998;9:470-5.

  24. Davidson, BL, Stein, CS, Heth, JA, et al. Recombinant adenoassociated virus type 2, 4, and 5 vectors: transduction of variant cell types and regions in the mammalian central nervous system. Proc Natl Acad Sci U S A 2000;97:3428-32.

  25. Gao, GP, Alvira, MR, Wang, L, Calcedo, R, Johnston, J and Wilson, JM. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci U S A 2002;99:11854-9.

  26. Duverger, V, Sartorius, U, Klein-Bauernschmitt, P, Krammer, PH and Schlehofer, JR. Enhancement of cisplatin-induced apoptosis by infection with adeno-associated virus type 2. Int J Cancer 2002;97:706- 12.

  27. Glorioso, JC, DeLuca, NA and Fink, DJ. Development and application of herpes simplex virus vectors for human gene therapy. Annu Rev Microbiol 1995;49:675-710.

  28. Kim, SH, Yu, SS, Park, JS, Robbins, PD, An, CS and Kim, S. Construction of retroviral vectors with improved safety, gene expression, and versatility. J Virol 1998;72:994-1004.

  29. Vigna, E and Naldini, L. Lentiviral vectors: excellent tools for experimental gene transfer and promising candidates for gene therapy. J Gene Med 2000;2:308-16.

  30. Kay, MA, Glorioso, JC and Naldini, L. Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat Med 2001;7:33-40.

  31. Kommareddy, S, Tiwari, SB and Amiji, MM. Long-circulating polymeric nanovectors for tumor-selective gene delivery. Technol Cancer Res Treat 2005;4:615-25.

  32. He, TC, Zhou, S, da Costa, LT, Yu, J, Kinzler, KW and Vogelstein, B. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci U S A 1998;95:2509-14.

  33. Dmitriev, I, Krasnykh, V, Miller, CR, Wang, M, Kashentseva, E, Mikheeva, G, Belousova, N and Curiel, DT. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J Virol 1998;72:9706-13.

  34. van Beusechem, VW, van Rijswijk, AL, van Es, HH, Haisma, HJ, Pinedo, HM and Gerritsen, WR. Recombinant adenovirus vectors with knobless fibers for targeted gene transfer. Gene Ther 2000;7:1940- 6.

  35. Li, ZB, Zeng, ZJ, Chen, Q, Luo, SQ and Hu, WX. Recombinant AAV-mediated HSVtk gene transfer with direct intratumoral injections and Tet-On regulation for implanted human breast cancer. BMC Cancer 2006;6:66.

  36. Gomez-Navarro, J and Curiel, DT. Conditionally replicative adenoviral vectors for cancer gene therapy. Lancet Oncol 2000;1:148- 58.

  37. Douglas, JT, Miller, CR, Kim, M, Dmitriev, I, Mikheeva, G, Krasnykh, V and Curiel, DT. A system for the propagation of adenoviral vectors with genetically modified receptor specificities. Nat Biotechnol 1999;17:470-5.

  38. Liu, XY, Gu, JF and Shi, WF. Targeting gene-virotherapy for cancer. Acta Biochim Biophys Sin (Shanghai) 2005;37:581-7.

  39. Li, X, Chen, G and Yang, B. Urea Transporter Physiology Studied in Knockout Mice. Front Physiol 2012;3:217.

  40. Cooper, DK, Ekser, B, Burlak, C, et al. Clinical lung xenotransplantation - what donor genetic modifications may be necessary? Xenotransplantation 2012;19:144-58.

  41. Park, JY, Park, MR, Bui, HT, et al. alpha1,3-Galactosyltransferase Deficiency in Germ-Free Miniature Pigs Increases NGlycolylneuraminic Acids As the Xenoantigenic Determinant in Pig- Human Xenotransplantation. Cell Reprogram 2012;14:353-63.

  42. Pelosi, A, Shepherd, R and Walmsley, AM. Delivery of plantmade vaccines and therapeutics. Biotechnol Adv 2012;30:440-8.

  43. Stocks, M. Intrabodies as drug discovery tools and therapeutics. Curr Opin Chem Biol 2005;9:359-65.

  44. Maguire-Zeiss, KA, Wang, CI, Yehling, E, et al. Identification of human alpha-synuclein specific single chain antibodies. Biochem Biophys Res Commun 2006;349:1198-205.

  45. Colby, DW, Chu, Y, Cassady, JP, et al. Potent inhibition of huntingtin aggregation and cytotoxicity by a disulfide bond-free single-domain intracellular antibody. Proc Natl Acad Sci U S A 2004;101:17616-21.

  46. Paganetti, P, Calanca, V, Galli, C, Stefani, M and Molinari, M. betasite specific intrabodies to decrease and prevent generation of Alzheimer’s Abeta peptide. J Cell Biol 2005;168:863-8.

  47. Corte-Real, S, Collins, C, Aires da Silva, F, Simas, JP, Barbas, CF, 3rd, Chang, Y, Moore, P and Goncalves, J. Intrabodies targeting the Kaposi sarcoma-associated herpesvirus latency antigen inhibit viral persistence in lymphoma cells. Blood 2005;106:3797-802.

  48. Griffin, H, Elston, R, Jackson, D, Ansell, K, Coleman, M, Winter, G and Doorbar, J. Inhibition of papillomavirus protein function in cervical cancer cells by intrabody targeting. J Mol Biol 2006;355:360- 78.

  49. Paz, K, Brennan, LA, Iacolina, M, Doody, J, Hadari, YR and Zhu, Z. Human single-domain neutralizing intrabodies directed against Etk kinase: a novel approach to impair cellular transformation. Mol Cancer Ther 2005;4:1801-9.




2020     |     www.medigraphic.com